Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
1(20%)
Results Posted
150%(3 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_3
3
60%
Ph phase_2
2
40%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(1)
Completed(2)
Terminated(2)

Detailed Status

Completed2
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 33 (60.0%)

Trials by Status

active_not_recruiting120%
completed240%
terminated240%

Recent Activity

1 active trials
Showing 5 of 5
active_not_recruitingphase_2

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

NCT05751187
terminatedphase_3

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

NCT04786964
completedphase_3

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

NCT02578680
completedphase_3

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

NCT03950674
terminatedphase_2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

NCT04265534

Clinical Trials (5)

Showing 5 of 5 trials
NCT05751187Phase 2

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Active Not Recruiting
NCT04786964Phase 3

Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC

Terminated
NCT02578680Phase 3

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)

Completed
NCT03950674Phase 3

Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Completed
NCT04265534Phase 2

KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
5